No Data
No Data
Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected
Chipscreen Biosciences Unit Gets China Nod to Trial Tumor Drugs; Shares Up 5%
Express News | Shenzhen Chipscreen Biosciences Co Ltd: Anti-Tumor Drug Cs231295 Tablets Ind Application Accepted
Shenzhen Chipscreen Biosciences (688321.SH): The clinical trial application for CS231295片 in the treatment of advanced solid tumors has been accepted.
Shenzhen Chipscreen Biosciences (688321.SH) announced that the company and its wholly-owned subsidiary Shenzhen Chipscreen Pharmaceutical Co., Ltd. recently...
Express News | Chiglitazar for the Treatment of Mash Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
Shenzhen Chipscreen Biosciences (688321.SH): The current design capacity of the two production lines for SGLT-2 inhibitors is 0.1 billion tablets.
On September 13th, Chipscreen Biosciences (688321.SH) disclosed the record of investor relations activities, which shows that the company's current design capacity for Selpercatinib is 0.1 billion tablets, and there is currently no shortage. At the same time, the company has completed the installation and commissioning of the Phase III expansion of Selpercatinib's production capacity and is currently conducting process validation production.
No Data
No Data